ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2

Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2. The active...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ZINIC, MLADEN, SUBOTIC, BORIS, MIKLOSKA, ZORKA
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ZINIC, MLADEN
SUBOTIC, BORIS
MIKLOSKA, ZORKA
description Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2. The active substance is represented by the synthetic zeolites in pure form, with defined crystal structures and chemical compositions. The active substance (zeolite) has a crystal size of 0.1-10 μm and specific surface of 400-1200 m2/g. The sodium ions can be partially or completely exchanged with other cations, e.g. K+, Ag+, NH4+, Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Fe2+ and Fe3+ in active substance of this antiviral compound. The carrier of active compound is the organic gel, water, oil, cream, liposome and liposome-based systems with regular and/or prolonged activity. The weight ratio between the active substance and the carrier is 5×10−9-10−3, i.e. 5 ng to 1 mg of active substance per one gram of the carrier. The additives used are vitamines: Vitamin C (0-20 wt. %), vitamin E (0-0.01 wt. %), vitamin A (0-1 wt. %) and vitamin D3 (0-1 wt. %). The efficacy of this preparation was demonstrated in in vitro experiments of the inhibition of HSV-1 and HSV-2 plaques formation in keratinocyte monolayers that were preincubated, coincubated or postincubated with the virus at the different time points (by up to 92%).
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP2296671A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP2296671A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP2296671A13</originalsourceid><addsrcrecordid>eNqNzEEKwjAUBNBuXIh6h7mAi1aouIztDw3UJCRptW5KkbgSLdR7eGUTFNeu_sC8-fPkdSZVC0fgyhyamjmhJJgs0ViCq8iQ4rGLGdpQS_JHYs10hyBKYYlZsihYGJbYdxCSUxGtxVG4CgHrAKw46JpOaIVpLFynCennW4zZMpldh9vkV9-7SMDJFdXaj4_eT-Nw8Xf_7Eln2S7PtylLN3-QN3-kP5s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2</title><source>esp@cenet</source><creator>ZINIC, MLADEN ; SUBOTIC, BORIS ; MIKLOSKA, ZORKA</creator><creatorcontrib>ZINIC, MLADEN ; SUBOTIC, BORIS ; MIKLOSKA, ZORKA</creatorcontrib><description>Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2. The active substance is represented by the synthetic zeolites in pure form, with defined crystal structures and chemical compositions. The active substance (zeolite) has a crystal size of 0.1-10 μm and specific surface of 400-1200 m2/g. The sodium ions can be partially or completely exchanged with other cations, e.g. K+, Ag+, NH4+, Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Fe2+ and Fe3+ in active substance of this antiviral compound. The carrier of active compound is the organic gel, water, oil, cream, liposome and liposome-based systems with regular and/or prolonged activity. The weight ratio between the active substance and the carrier is 5×10−9-10−3, i.e. 5 ng to 1 mg of active substance per one gram of the carrier. The additives used are vitamines: Vitamin C (0-20 wt. %), vitamin E (0-0.01 wt. %), vitamin A (0-1 wt. %) and vitamin D3 (0-1 wt. %). The efficacy of this preparation was demonstrated in in vitro experiments of the inhibition of HSV-1 and HSV-2 plaques formation in keratinocyte monolayers that were preincubated, coincubated or postincubated with the virus at the different time points (by up to 92%).</description><language>eng ; fre ; ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20110323&amp;DB=EPODOC&amp;CC=EP&amp;NR=2296671A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20110323&amp;DB=EPODOC&amp;CC=EP&amp;NR=2296671A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZINIC, MLADEN</creatorcontrib><creatorcontrib>SUBOTIC, BORIS</creatorcontrib><creatorcontrib>MIKLOSKA, ZORKA</creatorcontrib><title>ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2</title><description>Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2. The active substance is represented by the synthetic zeolites in pure form, with defined crystal structures and chemical compositions. The active substance (zeolite) has a crystal size of 0.1-10 μm and specific surface of 400-1200 m2/g. The sodium ions can be partially or completely exchanged with other cations, e.g. K+, Ag+, NH4+, Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Fe2+ and Fe3+ in active substance of this antiviral compound. The carrier of active compound is the organic gel, water, oil, cream, liposome and liposome-based systems with regular and/or prolonged activity. The weight ratio between the active substance and the carrier is 5×10−9-10−3, i.e. 5 ng to 1 mg of active substance per one gram of the carrier. The additives used are vitamines: Vitamin C (0-20 wt. %), vitamin E (0-0.01 wt. %), vitamin A (0-1 wt. %) and vitamin D3 (0-1 wt. %). The efficacy of this preparation was demonstrated in in vitro experiments of the inhibition of HSV-1 and HSV-2 plaques formation in keratinocyte monolayers that were preincubated, coincubated or postincubated with the virus at the different time points (by up to 92%).</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzEEKwjAUBNBuXIh6h7mAi1aouIztDw3UJCRptW5KkbgSLdR7eGUTFNeu_sC8-fPkdSZVC0fgyhyamjmhJJgs0ViCq8iQ4rGLGdpQS_JHYs10hyBKYYlZsihYGJbYdxCSUxGtxVG4CgHrAKw46JpOaIVpLFynCennW4zZMpldh9vkV9-7SMDJFdXaj4_eT-Nw8Xf_7Eln2S7PtylLN3-QN3-kP5s</recordid><startdate>20110323</startdate><enddate>20110323</enddate><creator>ZINIC, MLADEN</creator><creator>SUBOTIC, BORIS</creator><creator>MIKLOSKA, ZORKA</creator><scope>EVB</scope></search><sort><creationdate>20110323</creationdate><title>ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2</title><author>ZINIC, MLADEN ; SUBOTIC, BORIS ; MIKLOSKA, ZORKA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP2296671A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2011</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZINIC, MLADEN</creatorcontrib><creatorcontrib>SUBOTIC, BORIS</creatorcontrib><creatorcontrib>MIKLOSKA, ZORKA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZINIC, MLADEN</au><au>SUBOTIC, BORIS</au><au>MIKLOSKA, ZORKA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2</title><date>2011-03-23</date><risdate>2011</risdate><abstract>Antiviral medicine (compound) presented here is comprised of an active substance, a carrier of active substance and additives, and it is used for the prophylaxis, therapy and/or pre-respectively post-treatment of diseases caused by the infection with Herpes simplex virus type 1 and/or 2. The active substance is represented by the synthetic zeolites in pure form, with defined crystal structures and chemical compositions. The active substance (zeolite) has a crystal size of 0.1-10 μm and specific surface of 400-1200 m2/g. The sodium ions can be partially or completely exchanged with other cations, e.g. K+, Ag+, NH4+, Ca2+, Mg2+, Mn2+, Zn2+, Cu2+, Fe2+ and Fe3+ in active substance of this antiviral compound. The carrier of active compound is the organic gel, water, oil, cream, liposome and liposome-based systems with regular and/or prolonged activity. The weight ratio between the active substance and the carrier is 5×10−9-10−3, i.e. 5 ng to 1 mg of active substance per one gram of the carrier. The additives used are vitamines: Vitamin C (0-20 wt. %), vitamin E (0-0.01 wt. %), vitamin A (0-1 wt. %) and vitamin D3 (0-1 wt. %). The efficacy of this preparation was demonstrated in in vitro experiments of the inhibition of HSV-1 and HSV-2 plaques formation in keratinocyte monolayers that were preincubated, coincubated or postincubated with the virus at the different time points (by up to 92%).</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP2296671A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title ZEOLITE FORMULATION AND USE THEREOF FOR THE PREVENTION AND THERAPY OF DISEASES CAUSED BY INFECTIONS WITH HERPES SIMPLEX VIRUS TYPE 1 AND TYPE 2
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A18%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZINIC,%20MLADEN&rft.date=2011-03-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP2296671A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true